Table 1: Probabilities of receiving second-line treatments.

Regimen Probability of receiving second-line treatment in
ItalySpainSweden

Following first-line treatment with doxorubicin/ifosfamide
 CYVADIC<0.01<0.010.10
 Gemcitabine/dacarbazine<0.010.12<0.01
 Gemcitabine/docetaxel0.180.200.48
 Gemcitabine/paclitaxel<0.010.10<0.01
 Gemcitabine/vinorelbine<0.010.08<0.01
 Gemcitabine monotherapy<0.010.12<0.01
 Ifosfamide monotherapy0.200.12<0.01
 Liposomal doxorubicin0.12<0.01<0.01
 Trofosfamide<0.01<0.010.12
 Trabectedin monotherapy0.500.260.30
Following first-line treatment with trabectedin monotherapy
 Docetaxel monotherapy0.26<0.01<0.01
 Doxorubicin/ifosfamide<0.01<0.010.67
 Doxorubicin monotherapy<0.01<0.01<0.01
 Gemcitabine/docetaxel0.050.440.25
 Ifosfamide/epirubicin0.16<0.01<0.01
 Ifosfamide monotherapy0.530.56<0.01
 Trofosfamide/etoposide<0.01<0.010.08

CYVADIC: cyclophosphamide, vincristine, adriamycin, and dacarbazine.